Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients by Dickinson, L et al.
POSTER PRESENTATION Open Access
Population pharmacokinetic modelling of once-
daily ritonavir-boosted darunavir in HIV-infected
patients
L Dickinson
1*, AGA Jackson
2, LJ Garvey
3, V Watson
1, SH Khoo
4, A Winston
3, M Boffito
5, GR Davies
4, DJ Back
4
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Purpose of the study
Once daily ritonavir-boosted darunavir (DRV/RTV) is a
preferred antiretroviral regimen for treatment-naïve
patients. The pharmacokinetics (PK) of DRV/RTV may
be influenced by patient demographics and co-medica-
tions. Also with an increased aging HIV population,
investigations into the impact of older age on PK are
important.
Methods
Data were pooled from 3 DRV/RTV PK studies. In total
51 HIV-infected patients (7 female) stable on DRV/RTV
(800/100mg or 900/100mg once daily; n=32 and 19,
respectively) were included. Median age, weight, BMI,
RTV area under the curve over 24h (AUC0-24) and base-
line CD4 cell count were 39yr (21-63), 74kg (57-105),
24kg/m
2 (18-31), 4.35mg.h/L (2.27-10.99) and 500cells/
mm
3 (227-1129), respectively; 49 patients had undetect-
able viral load at time of study. PK sampling was per-
formed at steady-state and between 1-3 PK curves were
available per patient. Nonlinear mixed effects modelling
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PK parameters, interindividual and interoccasion varia-
bility and residual error. The following covariates were
evaluated: age, weight, BMI, sex, ethnicity, RTV AUC0-24
and raltegravir co-medication (400mg twice daily). The
model was validated by means of simulation and visual
predictive check.
Summary of results
A 2-compartment model with first-order absorption (ka
0.914h
-1) and lag-time (0.358h) best described the data.
Inclusion of a different apparent oral clearance (CL/F)
and volume of distribution (V2/F) for one of the studies
improved the fit (Study 1,2 vs. Study 3 CL/F: 12.5 vs.
15.6L/h; V2/F 125 vs. 192L). RTV AUC0-24 and age
were significantly associated with DRV CL/F. An
increase in age of 1yr produced a fractional decrease in
DRV CL/F of 0.014, equivalent to a 14% reduction in
CL/F with every 10yr increase in age. Based on the
visual predictive check 94% of observed DRV concentra-
tions were within the 95% prediction interval, indicative
of an adequate model.
Conclusions
A population model describing the PK of once daily
RTV-boosted DRV has been developed and validated.
RTV AUC0-24 and age were significantly related to DRV
CL/F. The impact of age requires further investigation
and clarification over a wide age range, particularly in
an elderly population.
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